Cover Story: Nav-i-gating antibodies for pain 

 

Table 1. Nav1.7 small molecule inhibitors and antibodies. Specifically blocking the Nav1.7 (SCN9A) voltage-gated sodium channel subtype suppresses pain. At least six companies have small molecule inhibitors or antibodies against Nav1.7 in clinical and preclinical testing to treat pain.

Source: BCIQ: BioCentury Online Intelligence

Company

Product

Description

Phase of development

Convergence Pharmaceuticals Ltd.

CNV1014802

Small molecule, state-dependent Nav1.7 inhibitor

Phase II

Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506)

DSP-2230

Small molecule inhibitor of Nav1.7 and Nav1.8 (PN3; SCN10A)

Phase I

Pfizer Inc. (NYSE:PFE)

PF-05089771

Small molecule Nav1.7 inhibitor

Phase I

SiteOne Therapeutics Inc.

ST-200

Small molecule Nav1.7 inhibitor

Discovery

arGEN-X B.V.

Nav1.7 antibodies

Antibodies against Nav1.7

Discovery

Numab AG

ND004

Antibody against Nav1.7

Discovery